Inotuzumab ozogamicin conditional pharmacokinetics

ALL reference fractionated regimen

Fixed inotuzumab ozogamicin amount model with a specified one-hour infusion history. Zero log deviations give typical coefficients, not a simulated population median.

Readouts

Central concentration · ng/mL

Serum model readout:1000 times central mg divided by apparent central L.

Exposure (AUC) · ng*h/mL

Nonfeedback integral of central serum concentration; physical hour-based AUC persists under alternative display clocks.

Clearance total · L/h

Fixed-context model quantity in the stated physical unit.

Accounted inotuzumab · mg

Current central and peripheral amounts plus integrated cumulative elimination.

Study purpose

• How do the model's key biological readouts change under all reference fractionated regimen?

Assumptions

• Fixed adult covariate and specified log-deviation contexts only; no patient estimation or population sampling.
• Disease and assay stratum were associated in the underlying adult analysis.
• The peripheral state is an apparent distribution amount, not a separately measured serum specimen.
• One-hour infusion duration is a specified approximation. Baseline covariates and log deviations remain fixed throughout each history.
• The absolute treatment clock never resets at later infusions. An infusion beginning at the observation endpoint delivers no amount before that endpoint.
• Cumulative eliminated amount integrates instantaneous total clearance times central concentration; exposure and accounting do not feed back.
• The clearance-arm decay half-time is not a terminal drug half-life.
• No explicit CD22 binding, tumor response, payload kinetics, clinical dose advice, original patient fit or population predictive check is represented.